BR9408377A - Composto composição farmacêutica processo para estimular a liberação de hormônio de crescimento da pituitária e uso do composto - Google Patents

Composto composição farmacêutica processo para estimular a liberação de hormônio de crescimento da pituitária e uso do composto

Info

Publication number
BR9408377A
BR9408377A BR9408377A BR9408377A BR9408377A BR 9408377 A BR9408377 A BR 9408377A BR 9408377 A BR9408377 A BR 9408377A BR 9408377 A BR9408377 A BR 9408377A BR 9408377 A BR9408377 A BR 9408377A
Authority
BR
Brazil
Prior art keywords
compound
stimulate
release
growth hormone
pharmaceutical composition
Prior art date
Application number
BR9408377A
Other languages
English (en)
Inventor
Nils Langeland Johansen
Jesper Lau
Kjeld Madsen
Behrend Friedrich Lundt
Henning Thogersen
Birgit Sehested Hansen
Bernd Peschke
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK143993A external-priority patent/DK143993D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9408377A publication Critical patent/BR9408377A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9408377A 1993-12-23 1994-12-22 Composto composição farmacêutica processo para estimular a liberação de hormônio de crescimento da pituitária e uso do composto BR9408377A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK143993A DK143993D0 (pt) 1993-12-23 1993-12-23
DK12194 1994-01-28
DK119194 1994-10-14
PCT/DK1994/000485 WO1995017423A1 (en) 1993-12-23 1994-12-22 Compounds with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
BR9408377A true BR9408377A (pt) 1997-08-19

Family

ID=27220421

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9408377A BR9408377A (pt) 1993-12-23 1994-12-22 Composto composição farmacêutica processo para estimular a liberação de hormônio de crescimento da pituitária e uso do composto

Country Status (27)

Country Link
US (1) US5767085A (pt)
EP (1) EP0736039B1 (pt)
JP (1) JP3181918B2 (pt)
KR (1) KR100354897B1 (pt)
CN (1) CN1052731C (pt)
AT (1) ATE197158T1 (pt)
AU (1) AU689181B2 (pt)
BR (1) BR9408377A (pt)
CA (1) CA2179597A1 (pt)
CZ (1) CZ293113B6 (pt)
DE (1) DE69426206T2 (pt)
DK (1) DK0736039T3 (pt)
ES (1) ES2153469T3 (pt)
FI (1) FI962584A0 (pt)
GR (1) GR3035150T3 (pt)
HU (1) HU224345B1 (pt)
IL (1) IL112112A (pt)
MX (1) MX9500072A (pt)
NO (1) NO315561B1 (pt)
NZ (1) NZ277486A (pt)
PL (1) PL181280B1 (pt)
PT (1) PT736039E (pt)
RO (1) RO115635B1 (pt)
SG (1) SG55069A1 (pt)
SK (1) SK281963B6 (pt)
UA (1) UA42747C2 (pt)
WO (1) WO1995017423A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176140A1 (en) * 1993-11-24 1995-06-01 Meng Hsin Chen Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
RU2167881C2 (ru) * 1993-12-23 2001-05-27 Ново Нордиск А/С Соединения, способствующие высвобождению гормона роста
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
MY113488A (en) * 1995-01-27 2002-03-30 Novo Nordisk As Compounds with growth hormone releasing properties
PL186520B1 (pl) * 1995-06-22 2004-01-30 Novo Nordisk As Związk o właściwościach uwalniania hormonu wzrostu, kompozycja farmaceutyczna zawierająca ten związek i jego zastosowanie
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
US6242199B1 (en) 1995-12-13 2001-06-05 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
DE69637855D1 (de) * 1995-12-22 2009-04-16 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
CA2252761A1 (en) * 1996-04-24 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5919777A (en) * 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
DE69734215T2 (de) * 1996-07-22 2006-06-29 Novo Nordisk A/S Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
AU3938797A (en) * 1996-08-29 1998-03-19 Novo Nordisk A/S Transdermal delivery of peptides
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US20030069177A1 (en) 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU7906998A (en) 1997-06-20 1999-01-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
ATE470671T1 (de) 1998-01-16 2010-06-15 Helsinn Therapeutics Us Inc Verbindungen mit wachstumshormon-freisetzender eigenschaft
US6919315B1 (en) * 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
CA2333857A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
JP2002522058A (ja) 1998-08-10 2002-07-23 メルク・アンド・カンパニー・インコーポレーテッド イヌ成長ホルモン分泌促進物質受容体
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
EP1141014B1 (en) 1999-01-06 2004-12-08 Genentech, Inc. Insulin-like growth factor (igf) i mutant variant
EP1930021A3 (en) 1999-02-18 2008-06-18 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
JP2003501394A (ja) * 1999-06-04 2003-01-14 ノボ ノルディスク アクティーゼルスカブ 延長された重度の疾患の異化状態の処理のための組成物
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
WO2004100933A1 (en) * 2003-05-19 2004-11-25 Warner-Lambert Company Llc Hard gelatin capsule containing titanium oxide with a controlled particle size and process for producing the same
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
PT2274978E (pt) 2003-09-12 2015-07-09 Ipsen Biopharmaceuticals Inc Métodos para tratamento da deficiência do fator de crescimento de tipo insulina i (igf-i)
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
EP1735055A1 (en) * 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP2008509930A (ja) * 2004-08-12 2008-04-03 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進物質を利用して胃腸系の運動性を刺激する方法
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US8536120B2 (en) * 2006-04-28 2013-09-17 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
EP2644618B1 (en) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
JP2010518158A (ja) * 2007-02-13 2010-05-27 ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド 成長ホルモン分泌促進物質を用いた細胞増殖性障害の治療方法
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
EP2440180B1 (en) * 2009-06-12 2014-08-27 Helsinn Healthcare S.A. Ipamorelin diacetate injection and infusion solutions
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
EP3148587B1 (en) 2014-05-30 2021-02-24 Pfizer Inc Carbonitrile derivatives as selective androgen receptor modulators
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2018183411A1 (en) 2017-03-28 2018-10-04 The Regents Of The University Of Michigan Small molecule dcn1 inhibitors and therapeutic methods using the same
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
AU549053B2 (en) * 1981-12-28 1986-01-09 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
JPH08502250A (ja) * 1992-09-25 1996-03-12 スミスクライン・ビーチャム・コーポレイション 成長ホルモン放出ペプチド
CA2176140A1 (en) * 1993-11-24 1995-06-01 Meng Hsin Chen Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)

Also Published As

Publication number Publication date
SK281963B6 (sk) 2001-09-11
EP0736039A1 (en) 1996-10-09
CN1052731C (zh) 2000-05-24
JPH09507217A (ja) 1997-07-22
EP0736039B1 (en) 2000-10-25
NO962665D0 (no) 1996-06-21
AU689181B2 (en) 1998-03-26
SK82096A3 (en) 1997-01-08
RO115635B1 (ro) 2000-04-28
ES2153469T3 (es) 2001-03-01
NO962665L (no) 1996-08-23
KR100354897B1 (ko) 2003-01-06
PL315113A1 (en) 1996-10-14
DE69426206T2 (de) 2001-05-17
DK0736039T3 (da) 2001-02-12
GR3035150T3 (en) 2001-04-30
IL112112A (en) 2000-06-29
CA2179597A1 (en) 1995-06-29
AU1272495A (en) 1995-07-10
WO1995017423A1 (en) 1995-06-29
HU224345B1 (hu) 2005-08-29
NZ277486A (en) 1997-03-24
NO315561B1 (no) 2003-09-22
JP3181918B2 (ja) 2001-07-03
FI962584A (fi) 1996-06-20
ATE197158T1 (de) 2000-11-15
DE69426206D1 (de) 2000-11-30
HUT73497A (en) 1996-08-28
PT736039E (pt) 2001-04-30
HU9501947D0 (en) 1995-11-28
CZ293113B6 (cs) 2004-02-18
CZ183496A3 (en) 1997-02-12
FI962584A0 (fi) 1996-06-20
US5767085A (en) 1998-06-16
CN1138335A (zh) 1996-12-18
SG55069A1 (en) 1998-12-21
PL181280B1 (pl) 2001-07-31
MX9500072A (es) 1997-05-31
UA42747C2 (uk) 2001-11-15
IL112112A0 (en) 1995-03-15

Similar Documents

Publication Publication Date Title
BR9408377A (pt) Composto composição farmacêutica processo para estimular a liberação de hormônio de crescimento da pituitária e uso do composto
GB2364304A (en) Novel tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
TR27835A (tr) Sübstitüe edilmis azadiokzasikloalkenler.
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
PT98710A (pt) Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem
ATE195740T1 (de) Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
PT99513A (pt) Processo para a preparacao de composicoes farmaceuticas contendo profarmacos de morfina para administracao topica por via transdermica
ES2170813T3 (es) Acidos 2,2-dicloroalcanocarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar la resistencia a la insulina.
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
ES2131528T3 (es) Nuevos polipeptidos y su uso.
ES2104133T3 (es) Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico.
NO972623L (no) Farmasöytisk blanding omfattende lamotrigin
BR9708854A (pt) Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e para aumentar a taxa e grau de crescimento de animais e uso de um composto
BR9507381A (pt) Composto uso de um composto processo para o tratamento de um manifero composição famacèutica e processo para a preparação de compostos
MX9102518A (es) Dicarbonatos y uretanos de acido 4,5,-dihidroxi y 4,5,8,-trihidroxi-9,10-dihidro-9,10-dioxi-2-1-antracencarboxilico que tiene actividad terapeutica.
MX9301723A (es) Derivados de carbinol di-arilo puenteados, composiciones y metodos de uso.
FI961054A0 (fi) Menetelmä 9-(2-hydroksi)etoksimetyyliguaniinin valmistamiseksi
BR9807785A (pt) Processo para a preparação do composto, e, composto
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
ES2140683T3 (es) Procedimiento para preparar compuestos de benzopirano.
MX9710377A (es) Compuestos con propiedades de liberacion de la hormona de crecimiento.
NO974687D0 (no) Kondenserte <beta>-carboliner

Legal Events

Date Code Title Description
FA Application withdrawn